STATICIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for STATICIN (STATICIN).
STATICIN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to its active metabolite, norSTATICIN. It is also a substrate of P-glycoprotein. |
| Excretion | Renal excretion of unchanged drug accounts for 70-80% of total clearance; biliary/fecal excretion accounts for 15-20%; <5% metabolized. |
| Half-life | 6-8 hours in adults with normal renal function; extends to 12-20 hours in moderate renal impairment (CrCl <30 mL/min). |
| Protein binding | 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.5-2.0 L/kg; indicates extensive tissue distribution, with high concentrations in lung, liver, and kidney. |
| Bioavailability | Oral: 40-50% due to first-pass metabolism; IM: 75-85%; IV: 100%. |
| Onset of Action | Oral: 1-2 hours (clinically significant effect at steady state after 3-5 doses); Intravenous: rapid, within 15-30 minutes. |
| Duration of Action | 12-24 hours following single oral dose; sustained effect with repeated dosing; clinical effect persists for 24-36 hours after last dose due to active metabolite. |
500 mg orally every 12 hours for 7-14 days.
| Dosage form | SOLUTION |
| Renal impairment | Creatinine clearance 30-50 mL/min: 500 mg every 24 hours; 15-29 mL/min: 500 mg every 48 hours; <15 mL/min or hemodialysis: 500 mg every 96 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: use contraindicated. |
| Pediatric use | For children ≥2 years: 15 mg/kg/dose orally every 12 hours, maximum 500 mg/dose. |
| Geriatric use | Use with caution; dose adjustment based on renal function; monitor for QT prolongation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for STATICIN (STATICIN).
| Breastfeeding | Excreted in human milk; M/P ratio 0.8. Potential for serious adverse reactions in nursing infants. Discontinue breastfeeding or discontinue drug, considering importance of drug to mother. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. Avoid in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
["Concomitant use with MAOIs or within 14 days of stopping MAOI therapy","Concomitant use with linezolid or intravenous methylene blue","Known hypersensitivity to STATICIN or any of its inactive ingredients","Concomitant use with pimozide"]
| Precautions | ["Clinical worsening and suicide risk","Serotonin syndrome","Bleeding abnormalities","Activation of mania/hypomania","Seizure risk","Angle-closure glaucoma","Hyponatremia","QT prolongation","Sexual dysfunction","Discontinuation syndrome"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, renal function, liver enzymes. Fetal ultrasound for growth and amniotic fluid volume. Doppler assessment of ductus arteriosus if used after 28 weeks. |
| Fertility Effects | May impair fertility in females due to hormonal disruption; reversible upon discontinuation. No data on male fertility. |